Everyone is rightly excited about the wall of amazing tech-enabled startups being born in Europe and Israel, disrupting massive industries including media, marketing, fashion, retail, travel, finance and transportation. However, there’s one incredibly disruptive startup based in London that is going after one of the biggest markets of all, and is so opaque it is largely unknown in the world of business – and, much to my chagrin, it’s also impossible to invest in.
Search Our Blog
- Twitter API is Currently Down.
Above the Crowd
Both Sides of the Table
First Round Capital
Master of 500 Hats
As the European startup ecosystem matures, you would expect young entrepreneurs to enjoy ever-increasing access to useful advice from mentors, business leaders, experienced entrepreneurs, legal advisors and investors. Yet, surprisingly, we continue to come across founders who have made significant mistakes in their early capital raises that we suspect go against their own instincts and jeopardize the foundations of the businesses they are building.
In 2010, the thirtieth year of SoftBank’s existence, its founder Masayoshi Son outlined the company’s vision for the next 30 years. He first set the context by zooming out to talk about how the world and the needs of humanity would evolve over the next 300 years, and stated his firm objective for SoftBank to survive at least that long. And then, zooming back in, explained that in this context, having a 30-year plan was absolutely essential.
There comes a time in the life-span of any large successful company when they consider an IPO. In fact, almost all of the technology companies, which we now consider to be great, such as ASOS, Google and Priceline, have 'gone public' en route to achieving that status.
Now, thanks to a combination of favourable market conditions and the underlying strength of the fundamentals in the technology sector, this is precisely the right moment for the next wave of potentially global businesses to be mulling over and preparing for the possibility of an IPO.
"The heresies of one age become, as they always do, the orthodoxies of the next.” So said Margaret Thatcher in 1979, but it could easily have been David Cameron at the Liaison Committee in Parliament yesterday. Whoever is in power, making Britain’s public services more efficient and effective means taking on the broken orthodoxy of Whitehall thinking.
Since 2007, Index Ventures has been the largest shareholder in a rising star of pharma companies, ProFibrix - a visionary company whose lead product aims to save lives and speed recovery for patients undergoing bleeding during surgery and after trauma.
Today, our belief in ProFibrix - and particularly in founder Jaap Koopman, PhD - has been justified with the news of their acquisition by The Medicines Company.
In 2010, in my blog, DrugBaron, I declared the death of incremental innovation and wrote the obituary. It didn’t seem a very bold statement at the time - increasing payor pressure was beginning to bite, and it seemed obvious that the entrenched practice of paying a premium for small (often imperceptible) improvements was passing...
A tidal wave of technological disruption is rolling through the financial services sector - and not before time, says Jan Hammer, partner at Index Ventures.
While many looked at Supercell’s phenomenal rise and assumed that, statistically speaking, its best days had to be behind it, my partners and I took the contrary view and decided to lead a €100 million investment in the company.
Budget 2013: We need action to open up UK equity markets to high growth companies says Robin Klein